The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
J&J presented the new analysis from three Phase III trials of Caplyta in MDD.
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback